Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic variants in C5 and poor response to eculizumab.
Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y. Nishimura J, et al. Among authors: kanakura y. N Engl J Med. 2014 Feb 13;370(7):632-9. doi: 10.1056/NEJMoa1311084. N Engl J Med. 2014. PMID: 24521109 Free article.
[The C5 gene polymorphism in patients with PNH].
Nishimura J, Kanakura Y. Nishimura J, et al. Among authors: kanakura y. Rinsho Ketsueki. 2015 Feb;56(2):103-10. doi: 10.11406/rinketsu.56.103. Rinsho Ketsueki. 2015. PMID: 25765788 Review. Japanese.
[Paroxysmal nocturnal hemoglobinuria (PNH)].
Nishimura J, Kanakura Y. Nishimura J, et al. Among authors: kanakura y. Nihon Rinsho. 2008 Mar;66(3):490-6. Nihon Rinsho. 2008. PMID: 18330025 Review. Japanese.
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M. Kanakura Y, et al. Int J Hematol. 2011 Jan;93(1):36-46. doi: 10.1007/s12185-010-0748-9. Epub 2011 Jan 12. Int J Hematol. 2011. PMID: 21222185 Clinical Trial.
Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Ozawa K, Omine M. Kanakura Y, et al. Int J Hematol. 2013 Oct;98(4):406-16. doi: 10.1007/s12185-013-1404-y. Epub 2013 Aug 11. Int J Hematol. 2013. PMID: 23934275 Clinical Trial.
Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, Shichishima T, Okamoto S, Nishimura JI, Ohyashiki K, Nakao S, Ando K, Kanda Y, Kawaguchi T, Nakakuma H, Harada D, Akiyama H, Kinoshita T, Ozawa K, Omine M, Kanakura Y. Ninomiya H, et al. Among authors: kanakura y. Int J Hematol. 2016 Nov;104(5):548-558. doi: 10.1007/s12185-016-2065-4. Epub 2016 Jul 27. Int J Hematol. 2016. PMID: 27464489
Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.
Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, Wada K, Matsuda T, Akiyama H, Ikezoe T, Chiba S, Kanda Y, Kawaguchi T, Shichishima T, Nakakuma H, Okamoto S, Nishimura JI, Kanakura Y, Ninomiya H. Ueda Y, et al. Among authors: kanakura y. Int J Hematol. 2018 Jun;107(6):656-665. doi: 10.1007/s12185-018-2409-3. Epub 2018 Jan 30. Int J Hematol. 2018. PMID: 29383624
420 results